Is DermTech, Inc. overvalued or undervalued?

As of 10 March 2020, DermTech, Inc. has moved from a grade of "does not qualify" to "risky." The company is currently considered overvalued based on its financial metrics. Key ratios include a P/E ratio of 0.00, an EV to EBIT of 0.39, and an EV to EBITDA of 0.42, all indicating significant financial distress and negative capital employed.
In comparison to its peers, DermTech's valuation stands out unfavorably. For instance, Cardiff Oncology, Inc. has a P/E ratio of -5.0384, while Lucid Diagnostics, Inc. also carries a risky designation with a P/E of -2.8046. Notably, Pro-Dex, Inc. is classified as very attractive with a P/E of 15.6736, highlighting the stark contrast in valuations within the sector. Overall, DermTech's financial performance and ratios suggest it is overvalued relative to its peers and the broader market context.